Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang City, Liaoning Province, People's Republic of China.
Drug Des Devel Ther. 2020 Jun 18;14:2423-2433. doi: 10.2147/DDDT.S253961. eCollection 2020.
Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for downstaging the primary tumor in the breast and the metastatic axillary lymph node. Accurate evaluations of the response to neoadjuvant chemotherapy provide important information on the impact of systemic therapies on breast cancer biology, prognosis, and guidance for further therapy. Moreover, pathologic complete response is a validated and valuable surrogate prognostic factor of survival after therapy. Evaluations of neoadjuvant chemotherapy response are very important in clinical work and basic research. In this review, we will elaborate on evaluations of the efficacy of neoadjuvant chemotherapy in breast cancer and provide a clinical evaluation procedure for neoadjuvant chemotherapy.
新辅助化疗在乳腺癌中的应用越来越多，尤其是在降期原发性乳腺癌和转移性腋窝淋巴结方面。准确评估新辅助化疗的反应可提供有关全身治疗对乳腺癌生物学、预后的影响的重要信息，并为进一步治疗提供指导。此外，病理完全缓解是治疗后生存的一个经过验证且有价值的替代预后因素。评估新辅助化疗反应在临床工作和基础研究中都非常重要。在这篇综述中，我们将详细阐述乳腺癌新辅助化疗疗效的评估，并提供新辅助化疗的临床评估程序。
